Pharming Group NV (AS:PHARM) — Market Cap & Net Worth
Market Cap & Net Worth: Pharming Group NV (PHARM)
Pharming Group NV (AS:PHARM) has a market capitalization of $746.74 Million (€638.72 Million) as of September 21, 2026. Listed on the AS stock exchange, this Netherlands-based company holds position #10324 globally and #56 in its home market, demonstrating a -0.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharming Group NV's stock price €0.92 by its total outstanding shares 696688239 (696.69 Million). Also see Pharming Group NV assets under control for a full breakdown of the balance sheet.
Pharming Group NV Market Cap History: 2015 to 2026
Pharming Group NV's market capitalization history from 2015 to 2026. Data shows growth from $227.98 Million to $746.74 Million (10.51% CAGR). Also see cash flow conversion of Pharming Group NV for how efficiently the company converts equity into cash flow.
Index Memberships
Pharming Group NV is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
AMS Small Cap
ASCX
|
$12.31 Billion | 6.07% | #4 of 21 |
Weight: Pharming Group NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pharming Group NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharming Group NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Pharming Group NV (PHARM) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.63x
Pharming Group NV's market cap is 2.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $227.98 Million | $11.84 Million | -$10.89 Million | 19.26x | N/A |
| 2016 | $176.75 Million | $16.69 Million | -$18.44 Million | 10.59x | N/A |
| 2017 | $922.02 Million | $107.52 Million | -$95.92 Million | 8.58x | N/A |
| 2018 | $616.99 Million | $154.58 Million | $28.59 Million | 3.99x | 21.58x |
| 2019 | $1.28 Billion | $189.33 Million | $40.54 Million | 6.74x | 31.49x |
| 2020 | $1.04 Billion | $228.39 Million | $37.75 Million | 4.54x | 27.45x |
| 2021 | $631.24 Million | $189.85 Million | $16.00 Million | 3.32x | 39.46x |
| 2022 | $882.92 Million | $205.62 Million | $13.67 Million | 4.29x | 64.57x |
| 2023 | $839.75 Million | $226.91 Million | -$9.76 Million | 3.70x | N/A |
| 2024 | $753.41 Million | $286.89 Million | -$10.64 Million | 2.63x | N/A |
Competitor Companies of PHARM by Market Capitalization
Companies near Pharming Group NV in the global market cap rankings as of September 21, 2026. Review PHARM goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pharming Group NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Pharming Group NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Pharming Group NV's market cap moved from $227.98 Million to $ 746.74 Million, with a yearly change of 10.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €746.74 Million | -35.71% |
| 2025 | €1.16 Billion | +54.16% |
| 2024 | €753.41 Million | -10.28% |
| 2023 | €839.75 Million | -4.89% |
| 2022 | €882.92 Million | +39.87% |
| 2021 | €631.24 Million | -39.07% |
| 2020 | €1.04 Billion | -18.85% |
| 2019 | €1.28 Billion | +106.93% |
| 2018 | €616.99 Million | -33.08% |
| 2017 | €922.02 Million | +421.66% |
| 2016 | €176.75 Million | -22.47% |
| 2015 | €227.98 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Pharming Group NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $746.74 Million USD |
| MoneyControl | $746.74 Million USD |
| MarketWatch | $746.74 Million USD |
| marketcap.company | $746.74 Million USD |
| Reuters | $746.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more